10 completed, 10 unknown, 5 recruiting, 3 active not recruiting. 13 Phase 2, 8 Phase 1, 7 Not applicable, 3 Phase 3.
Follow Antineoplastic Agents: new trials by email Literature Review of Antineoplastic Agents trials Research Report on Antineoplastic Agents
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38) Drug-coated balloon, Single antiplatelet therapy (SAPT), Dual antiplatelet therapy (DAPT) - Coronary Disease, Heart Diseases | Not applicable | Recruiting | Fondazione Ricerca e Innovazione Cardiovascolare ETS | 576 | 2026-01-10 | 2026-01-22 |
| A Real-World Study of Fecal Transplants for Cancer Therapy Side Effects Fecal microbiota transplantation (FMT) - Fecal Microbiota Transplantation (FMT), Gastrointestinal Neoplasms | Phase 1 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 90 | 2025-09-01 | 2026-01-06 |
| Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer Befotertinib combined Bevacizumab, Befotertinib combined platinum-based double chemotherapy - EGFR, Non-Small Cell Lung Cancer | Phase 2 | Recruiting | Peng Zhang | 60 | 2024-11-07 | 2025-01-06 |
| Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma Follow-up study of the treated cohort - Neoplasms, Kidney Neoplasms | Recruiting | Jinling Hospital, China | 39 | 2024-09-01 | 2025-12-05 | |
| A Study to Compare PK, Immunogenicity and Safety of Trastuzumab of Incepta Pharmaceuticals Ltd With Trastuzumab (Roche) Trastuzumab (proposed Trastuzumab biosimilar), Herclon - Breast Cancer, Breast Neoplasms | Phase 1 | Completed | Incepta Pharmaceuticals Ltd | 80 | 2024-01-23 | 2025-07-22 |
| Nivolumab Combined With Chemotherapy in the Treatment of Primary Tracheal Squamous Cell Carcinoma Nivolumab Injection [Opdivo] - Neoplasms, Carcinoma, Squamous | Phase 2 | Unknown | The First Affiliated Hospital of Guangzhou Medical University | 25 | 2023-10-01 | 2024-05-21 |
| A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) Abemaciclib, Abiraterone, Prednisone or Prednisolone - Prostatic Neoplasms, Neoplasm Metastasis | Phase 3 | Active not recruiting | Eli Lilly and Company | 925 | 2022-04-14 | 2026-07-01 |
| (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations BLU-451, Carboplatin, Pemetrexed - Lung Neoplasm Malignant, Carcinoma, Non-Small-Cell Lung | Phase 1 | Terminated | Blueprint Medicines Corporation | 103 | 2022-03-04 | 2025-02-10 |
| (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC BLU-701, osimertinib, carboplatin - Lung Neoplasm, Carcinoma, Non-Small-Cell Lung | Phase 1 | Terminated | Blueprint Medicines Corporation | 20 | 2022-01-13 | 2023-06-18 |
| Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery Hepatic arterial infusion chemotherapy, Folfox Protocol, Donafenib - Carcinoma, Carcinoma, Hepatocellular | Phase 2 | Completed | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 30 | 2021-12-27 | 2026-06-30 |
| Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma nivolumab, BMS-986253, Stereotactic Body Radiotherapy (SBRT) - Melanoma, Unresectable Solid Tumors | Phase 1 | Active not recruiting | Yana Najjar | 50 | 2021-11-29 | 2026-08-20 |
| Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma Anlotinib, Cisplatin, Carboplatin - Urothelial Carcinoma, Anlotinib | Phase 2 | Unknown | Tianjin Medical University Second Hospital | 53 | 2021-10-01 | 2021-09-01 |
| Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer Drug: Anlotinib, Drug: Carboplatin/Paclitaxel - Ovarian Neoplasms, Fallopian Tube Neoplasms | Phase 2 | Active not recruiting | Wenjun Cheng | 56 | 2021-08-24 | 2024-07-03 |
| (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC BLU-945, osimertinib - Lung Neoplasms, Carcinoma, Non-Small-Cell Lung | Phase 1 | Terminated | Blueprint Medicines Corporation | 177 | 2021-06-29 | 2025-02-10 |
| Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01) tislelizumab and BCG - Urinary Bladder Neoplasms, Urologic Neoplasms | Phase 1 / Phase 2 | Unknown | RenJi Hospital | 6 | 2021-06-01 | 2021-06-11 |
| Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer Niraparib, Bevacizumab - Ovarian Neoplasms, Fallopian Tube Neoplasms | Phase 2 | Unknown | Xiaoxiang Chen | 32 | 2020-11-06 | 2020-11-10 |
| Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Anlotinib, Olaparib - Ovarian Cancer, Ovarian and Fallopian Tube Cysts and Neoplasms | Phase 2 | Unknown | Xiaoxiang Chen | 68 | 2020-10-28 | 2020-10-30 |
| TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC TACE combined with sorafenib and PD-1 mAb - Hepatocellular Carcinoma, Liver Neoplasms | Phase 2 | Completed | Sichuan Cancer Hospital and Research Institute | 27 | 2020-09-14 | 2024-06-25 |
| Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma CYNK-001 - Multiple Myeloma, Neoplasm, Plasma Cell | Phase 1 | Unknown | Celularity Incorporated | 29 | 2020-05-12 | 2023-02-16 |
| Cardiovascular Prevention Strategies in Elderly Patients With Cancer (CARTIER Clinical Trial) Intensive cardiovascular monitoring, No intervention - Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma), Elderly | Not applicable | Recruiting | Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León | 514 | 2019-08-02 | 2025-03-21 |
Showing 20 of 31. Sign in to see all of them.
Neoplasms (11) · Carcinoma (8) · Neoplasms by Histologic Type (8) · Neoplasms by Site (7) · Urogenital Neoplasms (7) · Breast Neoplasms (6) · Carcinoma, Non-Small-Cell Lung (4) · Adenocarcinoma (3) · Bronchial Neoplasms (3) · Carcinoma, Bronchogenic (3) · Carcinoma, Ovarian Epithelial (3) · Genital Diseases, Female (3) · Genital Neoplasms, Female (3) · Lung Diseases (3) · Lung Neoplasms (3)
Neoplasms by Site (18) · Neoplasms (15) · Female Urogenital Diseases and Pregnancy Complications (8) · Neoplasms, Glandular and Epithelial (8) · Urogenital Diseases (8) · Female Urogenital Diseases (7) · Male Urogenital Diseases (7) · Neoplasms by Histologic Type (7) · Skin Diseases (7) · Skin and Connective Tissue Diseases (7) · Genital Diseases (6) · Digestive System Diseases (5) · Breast Diseases (4) · Adenocarcinoma (3) · Bronchial Diseases (3)
Carboplatin (4) · anlotinib (4) · Nivolumab (2) · Pemetrexed (2) · osimertinib (2) · Bevacizumab (1) · CP protocol (1) · Cetuximab (1) · Cisplatin (1) · Control Groups (1) · Drug Therapy (1) · Echocardiography, Doppler (1) · Fecal Microbiota Transplantation (1) · Fluorouracil (1) · Folfox protocol (1)
Blueprint Medicines Corporation (3) · Xiaoxiang Chen (2) · Armando Orlandi (1) · Bassett Healthcare (1) · Celularity Incorporated (1) · Centro di Riferimento Oncologico - Aviano (1) · Eli Lilly and Company (1) · Fondazione Ricerca e Innovazione Cardiovascolare ETS (1) · Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León (1) · Incepta Pharmaceuticals Ltd (1) · Instituto Nacional de Cancerologia de Mexico (1) · Jinling Hospital, China (1) · Luzerner Kantonsspital (1) · National Cancer Institute, Slovakia (1) · Novartis Pharmaceuticals (1)
China (14) · United States (7) · Italy (4) · South Korea (4) · Canada (3) · Germany (3) · Japan (3) · Spain (3) · Taiwan (3) · France (2) · Mexico (2) · Netherlands (2) · United Kingdom (2) · Argentina (1) · Australia (1)
Xiaoxiang Chen, MD,PhD (2) · Adrian Kilcoyne, MD (1) · Bo Xu, professor (1) · Byeong-Woo Park, M.D.,ph.D. (1) · Claudia H Arce Salinas, MD (1) · Fabio Puglisi, MD (1) · Jae-Gook Shin, M.D.,ph.D. (1) · Kristina Loeffler, RN (1) · Lei Zhang, PHD (1) · Manindranath Roy (1) · Michael Mallmann, MD (1) · Michal Mego, prof (1)
PMID 11226762, PMID 12686700, PMID 12697943, PMID 1352024, PMID 15139073, PMID 16766588, PMID 17187507, PMID 17530482, PMID 18525044, PMID 19037667, PMID 20972805, PMID 21533811, PMID 22488022, PMID 23358260, PMID 24761161, PMID 25012726, PMID 25106522, PMID 3281702, PMID 3544842, PMID 38181312, PMID 39814492, PMID 6681766, PMID 9789602
2014 (1)